Dr. Rishi Raj is an Clinical Professor of Medicine at Stanford University and directs the Interstitial Lung Disease program at Stanford. He specializes in the diagnosis and treatment of interstitial lung diseases and has practiced pulmonary and critical care medicine for more than 15 years. Dr. Raj's primary clinical interest and primary focus of clinical research is interstitial lung diseases including idiopathic pulmonary fibrosis, other idiopathic interstitial lung diseases, drug induced interstitial lung diseases, interstitial lung disease associated with connective tissue diseases including scleroderma, rheumatoid arthritis, dermatomyositis etc., sarcoidosis, hypersensitivity pneumonitis and other miscellaneous interstitial lung diseases. Dr. Raj is the principal investigator and co-investigator on multiple clinical trials evaluating new therapies for treating idiopathic pulmonary fibrosis and pulmonary fibrosis/interstitial lung disease from other etiologies.
- Idiopathic Pulmonary Fibrosis
- Other Idiopathic Interstitial Lung Diseases
- Connective Tissue Associated Interstitial Lung Disease (RA, Scleroderma, Myosites, others)
- Drug Induced Interstitial Lung Diseases
- Hypersensitivity Pneumonitis
- Other Interstitial Lung Diseases
- Pulmonary Disease
Clinical Professor, Medicine - Pulmonary & Critical Care Medicine
Director, Interstitial Lung Disease Program, Stanford (2017 - Present)
Board Certification: Critical Care Medicine, American Board of Internal Medicine (2003)
Board Certification: Pulmonary Disease, American Board of Internal Medicine (2002)
Fellowship:Baylor College of Medicine Registrar (2002) TX
Board Certification: Internal Medicine, American Board of Internal Medicine (1999)
Residency:Texas Tech University Health Sciences Center (1999) TX
Internship:Texas Tech University Health Sciences Center (1997) TX
Medical Education:Christian Medical College/Vellor (1995)
Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry
2019; 20: 105
Idiopathic pulmonary fibrosis (IPF) is a progressive disease with a variable clinical course and high mortality. We used data from a large national US registry of patients with IPF to investigate relationships between patient characteristics, including markers of disease severity, and mortality.The analysis cohort comprised patients enrolled in the IPF-PRO Registry from its inception on 5 June 2014 to 26 October 2017. The primary criterion for inclusion in this registry is that patients must be diagnosed or confirmed with IPF at the enrolling centre within 6 months. Associations between patient characteristics and markers of disease severity at enrolment and mortality outcomes were investigated using univariable, multivariable and adjustment models.Among 662 patients enrolled, 111 patients died or had a lung transplant over a follow-up period of 30 months. The probability of being free of both events at month 30 was 50.6% (95% CI: 40.0, 60.2). When patient characteristics and markers of disease severity were jointly examined in a multivariable analysis, oxygen use at rest (hazard ratio [HR] 2.44 [95% CI: 1.45, 4.10]), lower forced vital capacity (FVC) % predicted (HR 1.28 [95% CI: 1.10, 1.49] per 10% decrease) and diffusion capacity for carbon monoxide (DLco) % predicted (HR 1.25 [95% CI: 1.04, 1.51] per 10% decrease) were significantly associated with increased risk of death or lung transplant. The risk of death or lung transplant increased with increasing age in patients ≥62 years old (HR 1.18 [95% CI: 0.99, 1.40] per 5-year increase), and decreased with increasing age in patients <62 years old (HR 0.60 [95% CI: 0.39, 0.92] per 5-year increase).In an observational US registry of patients with IPF, oxygen use at rest, lower FVC % predicted, and lower DLco % predicted were associated with risk of death or lung transplant. An audio podcast of the lead author discussing these data can be downloaded from: http://www.usscicomms.com/respiratory/snyder/IPF-PROsurvival1/ .ClinicalTrials.gov number: NCT01915511 .
View details for DOI 10.1186/s12931-019-1043-9
View details for Web of Science ID 000469504900001
View details for PubMedID 31142314
View details for PubMedCentralID PMC6542049
Tissue Continues to Be the Issue: Role of Histopathology in the Context of Recent Updates in the Radiologic Classification of Interstitial Lung Diseases.
Archives of pathology & laboratory medicine
2019; 143 (1): 30–33
High-resolution computed tomography (HRCT) imaging has an increasingly important role in clinical decision-making in patients with interstitial lung diseases. The recent Fleischner Society white paper on the diagnostic criteria for idiopathic pulmonary fibrosis highlights the advances in our understanding of HRCT imaging in interstitial lung diseases.To discuss the evidence and recommendations outlined in the white paper as it pertains to the radiologic diagnosis of interstitial lung disease, specifically highlighting the current limitations of HRCT in confidently predicting histopathologic findings.The recent Fleischner Society white paper and other studies pertaining to the role of HRCT in predicting histopathology in interstitial lung diseases are reviewed.High-resolution computed tomography is highly predictive of a usual interstitial pneumonia (UIP) pattern on histopathology when the HRCT shows a typical UIP pattern on a "confident" read by the radiologist. A probable UIP pattern is also very predictive of a UIP pattern on histopathology, and histopathologic confirmation is not needed for most patients demonstrating this pattern in the appropriate clinical setting. A UIP pattern may be seen in a substantial proportion of patients with an "indeterminate UIP" pattern on HRCT and in many patients for whom the HRCT suggests an alternative diagnosis; histopathologic confirmation should be considered in patients demonstrating these patterns whenever feasible.
View details for PubMedID 30785335
- Tissue Continues to Be the Issue Role of Histopathology in the Context of Recent Updates in the Radiologic Classification of Interstitial Lung Diseases ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE 2019; 143 (1): 30–33
Rituximab Versus Mycophenolate Mofetil in Interstitial Lung Disease Secondary to Connective Tissue Disease
View details for Web of Science ID 000447268902402